Preventing Crisis in Cardiology Care: Roadmap to the FuturePresented by the Johns Hopkins University School of Medicine. ACKNOWLEDGEMENT TUITION DATE OF RELEASE/EXPIRATION ESTIMATED TIME TO COMPLETE ACTIVITY DIRECTORS CREDIT DESIGNATION STATEMENTS OTHER CREDITS American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 12.0 hours of credit for completing this program. JOHNS HOPKINS STATEMENT OF RESPOSIBILITY INTENDED AUDIENCE PREREQUISITES STATEMENT OF NEED LEARNING OBJECTIVES
COURSE FORMAT PRE AND POST TEST AND EVALUATION DISCLAIMER STATEMENT INTERNET CME POLICY HIPAA STATEMENT CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes. I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations(the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu. “The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.” For CME Questions, please contact the CME Office at (410) 955-2959 or e-mail cmenet@jhmi.edu. Johns Hopkins University School of Medicine Reviewed & Approved by:
Acute Coronary Syndrome Education SummitHow Do We Optimize Patient Outcomes with Antiplatelet and Anticoagulant Therapies?Presented by the Johns Hopkins University School of Medicine. ACKNOWLEDGEMENT TUITION DATE OF RELEASE/EXPIRATION ESTIMATED TIME TO COMPLETE ACTIVITY DIRECTORS ACCREDITATION STATEMENT CREDIT DESIGNATION STATEMENTS OTHER CREDITS American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 3.75 hours of Category 1 credit for completing this program. JOHNS HOPKINS STATEMENT OF RESPOSIBILITY INTENDED AUDIENCE PREREQUISITES STATEMENT OF NEED After participating in this activity, the participant will demonstrate the ability to:
Full Disclosure Policy Affecting CME Activities
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
No other planners have indicated that they have any financial interests or relationships with a commercial entity. OFF-LABEL PRODUCT DISCUSSION
COURSE FORMAT PRE AND POST TEST AND EVALUATION DISCLAIMER STATEMENT INTERNET CME POLICY
Atrial Fibrillation Education Summit
|
|
FACULTY NAME AND LECTURE TITLE(S) |
RELATIONSHIP(S): |
|
Michael D Ezekowitz, MD |
Research Funding: Boehringer Ingelheim, ARYx Therapeutics, Portola, Daiichi Sankyo |
|
Joanne Foody, MD |
Consultant: Boehringer Ingelheim |
|
Christian Ruff, MD |
Research Funding: Merck, AstraZeneca |
|
Samuel Goldhaber, MD |
Research Funding: Boehringer Ingelheim, Bristol Myers Squibb, Eisai, EKOS, Johnson & Johnson, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Roxana Mehran, MD |
Research Funding: The Medicines Company, Bristol Myers Squibb, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Eric R. Bates, MD |
Advisor: Daiichi Sankyo, Eli Lilly, Sanofi Aventis, Merck, AstraZeneca |
|
Matthew Price, MD |
Research Funding: Bristol Myers Squibb, Sanofi Aventis, Accumetrics |
|
Deepak Bhatt, MD |
Research Funding: AstraZeneca, Bristol Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company |
|
Peter H. Jones, MD |
Consultant: Merck, Atherotech, Genentech, Abbott |
|
Vijay Nambi, MD |
Research Funding: NIH/NHLBI, |
|
Howard Weintraub, MD |
Advisor: AstraZeneca, Abbott, Takeda, Kowa, Novartis, Daiichi Sankyo |
|
Antonio Gotto, MD |
Consultant: AstraZeneca, KOWA, Merck |
|
Robert P. Giugliano, MD |
Research Funding: Amgen |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
|
Peter Kwiterovich, MD |
Research Funding: Abbott, GlaxoSmithKline, Merck, Pfizer |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
|
PLANNER’S NAME |
RELATIONSHIP(S) |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME AND LECTURE TITLE(S)
PRODUCT
Michael D Ezekowitz, MD
Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Tecarfarin, Ximelagatran, Dabigatran, Apixaban, Betrixaban, Edoxaban, Idraparinux, Rivaroxaban, YM150
Christian Ruff, MD
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients’ Needs
Apixaban, Edoxaban, Betrixaban, Eribaxaban, Razaxaban, Rivaroxaban, YM150, LY517717,
TAK 442, AZD0837, MCC 977, TTP889
Gregg W. Stone, MD
Keynote Address: The State of Interventional Cardiology
MitraClip, Sapien heart valve, Resolute
Roxana Mehran, MD
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Antiplatelet agents in PCI
Matthew Price, MD
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Clopidogrel, Prasugrel, Ticagrelor
William O’Neill, MD
Stents in Patients With Stable Angina: Overused or Misunderstood?
Impella
Peter H. Jones, MD
Optimizing Current Strategies With Statins: A Focus on New Evidence
Vytorin (simvastatin/ezetimibe)
Howard Weintraub, MD
Moving Beyond Statin Treatment in Dyslipidemias
Vytorin(Ezetimibe/Simvastatin), Anacetrapib, Dalcetrapib, Aleglitazar, Laropiprant,Ezetimibe, Simvastatin, Mipomerson, MTP Inhibitor
Robert P. Guigliano, MD
Emerging Therapies and Their Role in Comprehensive Lipid Management
Anacetrapib, Dalcetrapib, Torcetrapib, PCSK-9 Inhibitors
No other speakers have indicated that they intend to reference unlabeled/unapproved uses of drugs or devices.
Diabetes Education Summit
Diabetes Today: Individualized Approaches to Effective Management
Presented by the Johns Hopkins University School of Medicine
ACKNOWLEDGEMENT
Supported by an educational grant from Novo Nordisk and Lilly USA.
TUITION
Complimentary
DATE OF RELEASE/EXPIRATION
Live sessions will be available July 28, 2011 from 11:00 AM-4:00 PM (EST). These presentations will be on-demand from July 28, 2011 to January 28, 2012 at www.CardioCareLive.com
ESTIMATED TIME TO COMPLETE
Each activity will take approximately one hour to complete, for a total of 4 hours.
ACTIVITY DIRECTORS
Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at the Johns Hopkins University School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.
Christopher P. Cannon, MD, Associate Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4 hours of Category 1 credit for completing this program.
JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
INTENDED AUDIENCE
Endocrinologists, cardiologists, internal medicine practitioners, geriatricians, and family practice and primary care physicians involved in caring for diabetes patients will be targeted as the primary audience for this event. Secondary audiences will include diabetes nurses and nurse practitioners, diabetes educators, physician assistants, and pharmacists.
PREREQUISITES
There are no prerequisites.
STATEMENT OF NEED
The need for this educational activity has been established according to ACCME standards by expert assessment of a wide range of sources, including in-depth review of relevant medical literature, analysis of available quality of care and practice gap studies, and expert opinion as reflected in the faculty members' choices of topics and content. The resulting educational activity will include fair and balanced information on relevant therapies, including efficacy, side effects, and a discussion of adverse events if warranted. It will make use of clinical data that is as up-to-date as possible, including clinical trial results recently presented at major US meetings, such as those of the American Diabetes Association, the American Association of Clinical Endocrinologists, and the Endocrine Society, as well as international meetings such as the European Society of Endocrinology and important regional meetings. Content will also include clinical data recently published in major peer-reviewed journals and input from acknowledged experts and experienced clinicians in the fields of cardiology, endocrinology, internal medicine, geriatrics, family practice medicine, and others.
LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
- Assess current evidence-based guidelines for diabetes management and make practice modifications that improve glycemic control as well as control of cardiovascular risk factors in diabetes patients
- Evaluate clinical trial results on current and emerging antiglycemic therapies and make appropriate, individualized choices for diabetes patients with differing clinical characteristics
- Institute effective management strategies for diabetes patients who are older and/or who have multiple co-morbidities
- Develop evidence-based, long term management plans for diabetes patients that take into account patient characteristics including age, co-morbidities, length of time with the disease, self management abilities, and other important factors that may influence success in realizing glycemic goals.
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
| FACULTY NAME AND LECTURE TITLE(S) |
RELATIONSHIP(S): |
|
Stephen D. Wiviott, MD |
Research Funding: Eli Lilly, Daiichi Sankyo, Merck/Schering-Plough Consultant: Sanofi, Bristol-Myers Squibb, Portola, AstraZeneca, Medco, ARENA |
|
Deepak Bhatt, MD |
Research Funding: Astra Zeneca, Bristol-Myers Squibb, Eisai, Sanofi, The Medicines Company |
|
Marc Sabatine, MD |
Research Funding: Amgen, AstraZeneca, Bristol-Myers Squibb /Sanofi, Daiichi-Sankyo, Sanofi, Nanosphere Consultant: Bristol-Myers Squibb /Sanofi, Daiichi-Sankyo/Lilly, Sanofi Honorarium: Cardiovascular Research Forum, Eli Lilly |
|
Michael Gibson, MD |
Research Funding: Abbott, Angel Medical Corporation, Astra Zeneca, Atrium Medical Systems, Baxter Healthcare, Bayer Corp, FoldRx, Genentech, Inc., Johnson & Johnson Corporation, Lantheus Medical Imaging, Roche Diagnostics, Sanofi, Ikaria, Inc., Consultant: Angel Medical Systems, Inc., Daiichi Sankyo Company, Inc, Eli Lilly and Company, Schering Plough Corporation, The Medicines Company, Bayer Corporation, Biogen Idec, Bristol-Meyers Squibb, GlaxoSmithKline, Heartscape Technologies, Inc, ICON Medical Imaging |
|
Benjamin M. Scirica, MD |
Research Funding: Merck, Bristol-Myers Squibb, AstraZeneca, Gilead, Daiichi-Sankyo, Johnson&Johnson, Bayer Healthcare Consultant: Gilead, Lexicon, Arena |
|
Michelle O’Donoghue, MD |
Research Funding: AstraZeneca, GlaxoSmithKline, Eisai |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi, Novartis, Alnylam |
|
Jeff Popma, MD |
Research Grant: Medtronic, Abbot Vascular, Boston Scientific, Cadis Consultant: AstraZeneca, Boston Scientific |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi, Novartis, Alnylam |
|
Alan Cheng, MD |
Consultant: Biotronik Honorarium: Boston Scientific, Medtronic, St. Jude Medical |
|
Nicolas Musi, MD |
Consultant: Merck |
|
Richard W. Nesto, MD |
Consultant: Sanofi, Merck, Roche/Genentech |
|
Joanne Foody, MD |
Consultant: Merck, Pfizer, Sanofi |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
|
PLANNER’S NAME |
RELATIONSHIP(S) |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi Aventis, Novartis, Alnylam |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note:? Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME AND LECTURE TITLE(S) |
PRODUCT |
|
Marc Sabatine, MD |
clopidogrel, otamixaban, rivaroxaban |
|
Yancy |
ivabradine |
|
Alan Cheng |
St. Jude Left Atrial Pressure Monitor |
COURSE FORMAT
Live sessions are approximately one hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.CardioCareLive.com
PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Heart Failure Education Summit
Evaluating Progress in Heart Failure
Presented by the Johns Hopkins University School of Medicine
ACKNOWLEDGEMENT
Supported by an educational grant from Boston Scientific, GE Healthcare and Thoratec.
TUITION
Complimentary
DATE OF RELEASE/EXPIRATION
Live sessions will be available July 27, 2011 from 2:00 PM-3:30 PM (EST).
ACTIVITY DIRECTORS
Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at the Johns Hopkins University School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.
Christopher P. Cannon, MD, Associate Physician, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this program.
JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
INTENDED AUDIENCE
Cardiologists, interventional cardiologists, intensive care specialists, heart failure specialists, internal medicine physicians, and cardio-thoracic surgeons involved in caring for patients with heart failure, will be targeted as the primary audience for this event. Secondary audiences will include primary care practitioners, family physicians, diabetologists, nurses, physician assistants, and pharmacists.
PREREQUISITES
There are no prerequisites.
STATEMENT OF NEED
The need for this educational activity has been established according to ACCME standards by expert assessment of a wide range of sources, including in-depth review of relevant medical literature, analysis of available quality of care and practice gap studies, and expert opinion as reflected in the faculty members' choices of topics and content. The resulting educational activity will include fair and balanced information on relevant therapies, including efficacy, side effects, and a discussion of adverse events if warranted. It will make use of clinical data that is as up-to-date as possible, including clinical trial results recently presented at major U.S. meetings, such as the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, as well as European and international meetings such as the European Society of Cardiology and the International Society of Cardiomyopathy and Heart Failure, and important regional meetings. Content will also include clinical data recently published in major peer-reviewed journals and input from acknowledged experts and experienced clinicians in the fields of cardiology, interventional cardiology, intensive care, and internal medicine.
LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
- Discuss the use of biomarkers to guide management of heart failure
- Evaluate recommendations of the updated guidelines on medical management of heart failure
- Assess the use of device therapies for heart failure patients and progress in this area
- Identify patients who could benefit from mechanical circulatory support
- Evaluate the potential for recent research on myocyte biology to transform disease management in patients with heart failure
- Review current tests used to assess heart failure risk and prognosis, including imaging studies and application of biomarkers
- Identify new approaches to treatment of patients with heart failure using pharmacotherapy
- Identify the impact of comorbidities in patients with heart failure
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
| FACULTY NAME AND LECTURE TITLE(S) |
RELATIONSHIP(S): |
|
Stephen D. Wiviott, MD |
Research Funding: Eli Lilly, Daiichi Sankyo, Merck/Schering-Plough Consultant: Sanofi, Bristol-Myers Squibb, Portola, AstraZeneca, Medco, ARENA |
|
Deepak Bhatt, MD |
Research Funding: Astra Zeneca, Bristol-Myers Squibb, Eisai, Sanofi, The Medicines Company |
|
Marc Sabatine, MD |
Research Funding: Amgen, AstraZeneca, Bristol-Myers Squibb /Sanofi, Daiichi-Sankyo, Sanofi, Nanosphere Consultant: Bristol-Myers Squibb /Sanofi, Daiichi-Sankyo/Lilly, Sanofi Honorarium: Cardiovascular Research Forum, Eli Lilly |
|
Michael Gibson, MD |
Research Funding: Abbott, Angel Medical Corporation, Astra Zeneca, Atrium Medical Systems, Baxter Healthcare, Bayer Corp, FoldRx, Genentech, Inc., Johnson & Johnson Corporation, Lantheus Medical Imaging, Roche Diagnostics, Sanofi, Ikaria, Inc., Consultant: Angel Medical Systems, Inc., Daiichi Sankyo Company, Inc, Eli Lilly and Company, Schering Plough Corporation, The Medicines Company, Bayer Corporation, Biogen Idec, Bristol-Meyers Squibb, GlaxoSmithKline, Heartscape Technologies, Inc, ICON Medical Imaging |
|
Benjamin M. Scirica, MD |
Research Funding: Merck, Bristol-Myers Squibb, AstraZeneca, Gilead, Daiichi-Sankyo, Johnson&Johnson, Bayer Healthcare Consultant: Gilead, Lexicon, Arena |
|
Michelle O’Donoghue, MD |
Research Funding: AstraZeneca, GlaxoSmithKline, Eisai |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi, Novartis, Alnylam |
|
Jeff Popma, MD |
Research Grant: Medtronic, Abbot Vascular, Boston Scientific, Cadis Consultant: AstraZeneca, Boston Scientific |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi, Novartis, Alnylam |
|
Alan Cheng, MD |
Consultant: Biotronik Honorarium: Boston Scientific, Medtronic, St. Jude Medical |
|
Nicolas Musi, MD |
Consultant: Merck |
|
Richard W. Nesto, MD |
Consultant: Sanofi, Merck, Roche/Genentech |
|
Joanne Foody, MD |
Consultant: Merck, Pfizer, Sanofi |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
|
PLANNER’S NAME |
RELATIONSHIP(S) |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca Honorarium: Pfizer, AstraZeneca Clinical Advisor: Automedics Medical Systems Advisory Board: Brystol Myers Squibb, Sanofi Aventis, Novartis, Alnylam |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note:? Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME AND LECTURE TITLE(S) |
PRODUCT |
|
Marc Sabatine, MD |
clopidogrel, otamixaban, rivaroxaban |
|
Yancy |
ivabradine |
|
Alan Cheng |
St. Jude Left Atrial Pressure Monitor |
COURSE FORMAT
Live sessions are approximately one hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.CardioCareLive.com
PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Interventional Cardiology Education Summit
The First Line Defense in Heart Disease: Interventional Cardiology in Action
Presented by the Johns Hopkins University School of Medicine.
ACKNOWLEDGEMENT
Supported by an educational grant from Daiichi Sankyo/Lilly and Boston Scientific.
TUITION
Complimentary
DATE OF RELEASE/EXPIRATION
Live sessions will be available June 28, 2011 from 2:00-7:00 PM (EST). These presentations will be on-demand from June 30, 2011 to December 30, 2011 at www.CardioCareLive.com
ESTIMATED TIME TO COMPLETE
Each activity will take approximately one hour to complete, for a total of 4 hours.
ACTIVITY DIRECTORS
Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at the Johns Hopkins University School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 credits™ Physicians should claim only credit commensurate with the extent of their participation in the activity number.
OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4 hours of Category 1 credit for completing this program.
JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
INTENDED AUDIENCE
Cardiologists, interventional cardiologists, cardiac surgeons, and internal medicine physicians will be targeted as the primary audience for this event. Secondary audiences will include primary care practitioners, family physicians, nurses, physician assistants, and pharmacists.
PREREQUISITES
There are no prerequisites.
STATEMENT OF NEED
The need for this educational activity has been established according to ACCME standards by expert assessment of a wide range of sources, including in-depth review of relevant medical literature, analysis of available quality of care and practice gap studies, and expert opinion as reflected in the faculty members' choices of topics and content. The resulting educational activity will include fair and balanced information on relevant medical procedures and therapies, including outcomes, efficacy, side effects, and a discussion of adverse events if warranted. It will make use of clinical data that are as up-to-date as possible, including clinical trial results recently presented at major U.S. meetings, such as the American College of Cardiology and the American Heart Association, as well as European and international meetings such as the European Society of Cardiology and the International Academy of Cardiology, and important regional meetings. Content will also include clinical data recently published in major peer-reviewed journals and input from acknowledged experts and experienced clinicians in the fields of cardiology, interventional cardiology, cardiac surgery, and others.
LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
- Evaluate the risk of stent thrombosis in various patient populations receiving either DES or BMS; develop effective strategies to minimize the frequency of thrombotic events after stenting
- Outline new performance measures for STEMI and integrate them into clinical practice when applicable; design and implement effective processes to improve key measures
- Investigate mechanisms for anti-platelet resistance; profile treatment options for patient who develop resistance to anti-platelet agents
- Identify benefits and risks of stenting in patients with stable angina
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.
COURSE FORMAT
Live sessions are approximately one hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.CardioCareLive.com
PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
|
FACULTY NAME AND LECTURE TITLE(S) |
RELATIONSHIP(S): |
|
Michael D Ezekowitz, MD |
Research Funding: Boehringer Ingelheim, ARYx Therapeutics, Portola, Daiichi Sankyo |
|
Joanne Foody, MD |
Consultant: Boehringer Ingelheim |
|
Christian Ruff, MD |
Research Funding: Merck, AstraZeneca |
|
Samuel Goldhaber, MD |
Research Funding: Boehringer Ingelheim, Bristol Myers Squibb, Eisai, EKOS, Johnson & Johnson, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Roxana Mehran, MD |
Research Funding: The Medicines Company, Bristol Myers Squibb, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Eric R. Bates, MD |
Advisor: Daiichi Sankyo, Eli Lilly, Sanofi Aventis, Merck, AstraZeneca |
|
Matthew Price, MD |
Research Funding: Bristol Myers Squibb, Sanofi Aventis, Accumetrics |
|
Deepak Bhatt, MD |
Research Funding: AstraZeneca, Bristol Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company |
|
Peter H. Jones, MD |
Consultant: Merck, Atherotech, Genentech, Abbott |
|
Vijay Nambi, MD |
Research Funding: NIH/NHLBI, |
|
Howard Weintraub, MD |
Advisor: AstraZeneca, Abbott, Takeda, Kowa, Novartis, Daiichi Sankyo |
|
Antonio Gotto, MD |
Consultant: AstraZeneca, KOWA, Merck |
|
Robert P. Giugliano, MD |
Research Funding: Amgen |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
|
Peter Kwiterovich, MD |
Research Funding: Abbott, GlaxoSmithKline, Merck, Pfizer |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
|
PLANNER’S NAME |
RELATIONSHIP(S) |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME AND LECTURE TITLE(S)
PRODUCT
Michael D Ezekowitz, MD
Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Tecarfarin, Ximelagatran, Dabigatran, Apixaban, Betrixaban, Edoxaban, Idraparinux, Rivaroxaban, YM150
Christian Ruff, MD
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients’ Needs
Apixaban, Edoxaban, Betrixaban, Eribaxaban, Razaxaban, Rivaroxaban, YM150, LY517717,
TAK 442, AZD0837, MCC 977, TTP889
Gregg W. Stone, MD
Keynote Address: The State of Interventional Cardiology
MitraClip, Sapien heart valve, Resolute
Roxana Mehran, MD
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Antiplatelet agents in PCI
Matthew Price, MD
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Clopidogrel, Prasugrel, Ticagrelor
William O’Neill, MD
Stents in Patients With Stable Angina: Overused or Misunderstood?
Impella
Peter H. Jones, MD
Optimizing Current Strategies With Statins: A Focus on New Evidence
Vytorin (simvastatin/ezetimibe)
Howard Weintraub, MD
Moving Beyond Statin Treatment in Dyslipidemias
Vytorin(Ezetimibe/Simvastatin), Anacetrapib, Dalcetrapib, Aleglitazar, Laropiprant,Ezetimibe, Simvastatin, Mipomerson, MTP Inhibitor
Robert P. Guigliano, MD
Emerging Therapies and Their Role in Comprehensive Lipid Management
Anacetrapib, Dalcetrapib, Torcetrapib, PCSK-9 Inhibitors
No other speakers have indicated that they intend to reference unlabeled/unapproved uses of drugs or devices.
Lipid Management Education Summit
Current and Future Therapies in Lipid Management with Focus on Residual Risk Reduction
Presented by the Johns Hopkins University School of Medicine.
ACKNOWLEDGEMENT
Supported by an educational grant from Merck & Co. and Daiichi Sankyo.
TUITION
Complimentary
DATE OF RELEASE/EXPIRATION
Live sessions will be available June 29, 2011 from 11:00AM-4:00 PM (EST). These presentations will be on-demand from June 30, 2011 to December 30, 2011 at www.CardioCareLive.com
ESTIMATED TIME TO COMPLETE
Each activity will take approximately one hour to complete, for a total of 4 hours.
ACTIVITY DIRECTORS
Roger S. Blumenthal, MD, Professor of Medicine, Division of Cardiology at the Johns Hopkins University School of Medicine, Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.
Christopher P. Cannon, MD, Associate Physician, Brigham and Women's Hospital; Associate Professor of Medicine, Harvard Medical School
ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 credits™ Physicians should claim only credit commensurate with the extent of their participation in the activity number.
OTHER CREDITS
XLN11433-02 "Cardio Care Live: June 2011 - Optimizing Current Strategies With Statins: A Focus on New Evidence"
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity have been assigned ACPE number 022-999-11-054-L01-P and will award 1.00 contact hour (0.1 CEU) of continuing pharmacy education credit in states that recognize ACPE providers.
Statements of credit will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes signing in at registration, attending the entire session for which credit is claimed, completing the activity evaluation and requesting credit online at conclusion of the activity. The College complies with the Accreditation Standards for Continuing Pharmacy Education.
XLN11433-03 "Cardio Care Live: June 2011 - Moving Beyond Statin Treatment in Dyslipidemias"
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity have been assigned ACPE number 022-999-11-055-L01-P and will award 1.00 contact hour (0.1 CEU) of continuing pharmacy education credit in states that recognize ACPE providers.
Statements of credit will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes signing in at registration, attending the entire session for which credit is claimed, completing the activity evaluation and requesting credit online at conclusion of the activity. The College complies with the Accreditation Standards for Continuing Pharmacy Education.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4 hours of Category 1 credit for completing this program.
JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
INTENDED AUDIENCE
Cardiologists, internal medicine physicians, family physicians, and primary care practitioners involved in caring for patients with dyslipidemias will be targeted as the primary audience for this event. Secondary audiences will include diabetologists, nurses, physician assistants, and pharmacists.
PREREQUISITES
There are no prerequisites.
STATEMENT OF NEED
The need for this educational activity has been established according to ACCME standards by expert assessment of a wide range of sources, including in-depth review of relevant medical literature, analysis of available quality of care and practice gap studies, and expert opinion as reflected in the faculty members' choices of topics and content. The resulting educational activity will include fair and balanced information on relevant therapies, including efficacy, side effects, and a discussion of adverse events if warranted. It will make use of clinical data that is as up-to-date as possible, including clinical trial results recently presented at major U.S. meetings, such as the American College of Cardiology, the American Heart Association, the Society of General Internal Medicine, as well as European and international meetings such as the European Society of Cardiology and the International Atherosclerosis Society, and important regional meetings. Content will also include clinical data recently published in major peer-reviewed journals and input from acknowledged experts and experienced clinicians in the fields of cardiology, interventional cardiology, intensive care, and internal medicine.
After participating in this activity, the participant will demonstrate the ability to:
- Evaluate safety and efficacy of non-statin therapies used in dyslipidemias; identify scenarios when non-statin treatment either alone or in combination may be particularly effective
- Profile new mechanisms of action being developed to target dyslipidemias; review new clinical research results
- Properly manage the residual risk; recognize the importance of increasing HDL cholesterol levels and decreasing triglyceride levels
- Enhance compliance with statin treatment; discuss new research in this area and apply appropriate statin-based regimens in various patient populations
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.
COURSE FORMAT
Live sessions are approximately one hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.CardioCareLive.com
PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
|
FACULTY NAME AND LECTURE TITLE(S) |
RELATIONSHIP(S): |
|
Michael D Ezekowitz, MD |
Research Funding: Boehringer Ingelheim, ARYx Therapeutics, Portola, Daiichi Sankyo |
|
Joanne Foody, MD |
Consultant: Boehringer Ingelheim |
|
Christian Ruff, MD |
Research Funding: Merck, AstraZeneca |
|
Samuel Goldhaber, MD |
Research Funding: Boehringer Ingelheim, Bristol Myers Squibb, Eisai, EKOS, Johnson & Johnson, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Roxana Mehran, MD |
Research Funding: The Medicines Company, Bristol Myers Squibb, Sanofi Aventis |
|
Gregg W. Stone, MD |
Consultant: Boston Scientific, Abbott Vascular, Medtronics, The Medicines Company, Eli Lilly, Bristol Myers Squibb, Sanofi Aventis, AstraZeneca |
|
Eric R. Bates, MD |
Advisor: Daiichi Sankyo, Eli Lilly, Sanofi Aventis, Merck, AstraZeneca |
|
Matthew Price, MD |
Research Funding: Bristol Myers Squibb, Sanofi Aventis, Accumetrics |
|
Deepak Bhatt, MD |
Research Funding: AstraZeneca, Bristol Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company |
|
Peter H. Jones, MD |
Consultant: Merck, Atherotech, Genentech, Abbott |
|
Vijay Nambi, MD |
Research Funding: NIH/NHLBI, |
|
Howard Weintraub, MD |
Advisor: AstraZeneca, Abbott, Takeda, Kowa, Novartis, Daiichi Sankyo |
|
Antonio Gotto, MD |
Consultant: AstraZeneca, KOWA, Merck |
|
Robert P. Giugliano, MD |
Research Funding: Amgen |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
|
Peter Kwiterovich, MD |
Research Funding: Abbott, GlaxoSmithKline, Merck, Pfizer |
No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
|
PLANNER’S NAME |
RELATIONSHIP(S) |
|
Chris Cannon, MD |
Research Funding: GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda, Accumetrics, AstraZeneca |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
NAME AND LECTURE TITLE(S)
PRODUCT
Michael D Ezekowitz, MD
Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Tecarfarin, Ximelagatran, Dabigatran, Apixaban, Betrixaban, Edoxaban, Idraparinux, Rivaroxaban, YM150
Christian Ruff, MD
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients’ Needs
Apixaban, Edoxaban, Betrixaban, Eribaxaban, Razaxaban, Rivaroxaban, YM150, LY517717,
TAK 442, AZD0837, MCC 977, TTP889
Gregg W. Stone, MD
Keynote Address: The State of Interventional Cardiology
MitraClip, Sapien heart valve, Resolute
Roxana Mehran, MD
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Antiplatelet agents in PCI
Matthew Price, MD
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Clopidogrel, Prasugrel, Ticagrelor
William O’Neill, MD
Stents in Patients With Stable Angina: Overused or Misunderstood?
Impella
Peter H. Jones, MD
Optimizing Current Strategies With Statins: A Focus on New Evidence
Vytorin (simvastatin/ezetimibe)
Howard Weintraub, MD
Moving Beyond Statin Treatment in Dyslipidemias
Vytorin(Ezetimibe/Simvastatin), Anacetrapib, Dalcetrapib, Aleglitazar, Laropiprant,Ezetimibe, Simvastatin, Mipomerson, MTP Inhibitor
Robert P. Guigliano, MD
Emerging Therapies and Their Role in Comprehensive Lipid Management
Anacetrapib, Dalcetrapib, Torcetrapib, PCSK-9 Inhibitors
No other speakers have indicated that they intend to reference unlabeled/unapproved uses of drugs or devices.